Medicilon IncMedicilon IncMedicilon IncMedicilon Inc
  • Home
  • About
    • Medicilon Overview
    • Executive Team
    • CEO Message
    • Corporate Culture
    • Company History
    • Honor
  • Services
    • Integrated Projects
      • Antibody-Drug-Antibody (ADC)
      • Preclinical Research Services
      • IND Filing
      • Bio Drug Development
      • Chemical Drug Development
      • Chemical Compound Druggability Assessment
      • Molecular Imaging & Radiochemistry
      • OINDP Development
      • Preclinical Ophthalmic Research Platform
    • Pharmacology Services
      • Cancer Xenograft Models
      • Orthotopic Models
      • Syngeneic Mouse Models
      • Transgenic Mouse Model
      • Humanized Mouse Model (hPBMCEngrafted)
      • PDX Model
      • Digestive System Models
      • Neurological Disorders Models
      • Metabolic Disease Models
      • Inflammation & Immunological Disease Models
      • Other Disease Models
    • Chemistry Services
      • Medicinal Chemistry Services
      • Synthetic Chemistry
      • Process Development Services
      • Analytical Chemistry
    • Drug Formulation
      • Pre Formulation Development
      • Analytical Development
      • Formulation Development Services
      • Generics Consistency Evaluation
      • Research on Quality Control
      • Clinical Trial Material
      • OINDP Development
    • Biology Services
      • Discovery Biology Services
      • Recombinant Protein Services
      • Computational Biology & Molecular Modeling
      • Crystallization & Structural Determination
      • Kinase Services
      • SeMet Media Sales
    • Bioanalytical Services
      • Large Molecule Bioanalysis
      • Small Molecule Bioanalysis
    • Pharmacokinetic Services
      • In Vivo Assays
      • In Vitro Assays
    • Drug Safety Evaluation
      • Inhalation Toxicity Assessment
  • Customer
    • Customer Reviews
    • New Models of Collaboration
    • Intellectual Property Protection
    • Download Center
  • Careers
  • News
    • Medicilon Events
    • Media Coverage
    • Featured Stories
  • Contact

Lose the Weight, Escape the 8 Cancers

Home Featured Stories
NextPrevious

Lose the Weight, Escape the 8 Cancers

By medicilon | Featured Stories | 30 August, 2016 |

    New evidence published today by the International Agency for Cancer on Research (IARC), part of World Health Organization, provides even more of a reason to maintain a healthy weight as we age. The international team of researchers has identified eight additional types of cancer linked to excess weight and obesity: stomach, liver, gallbladder, pancreas, ovary, meningioma (a type of brain tumor), thyroid cancer, and the blood cancer multiple myeloma.


    In 2002 the same group produced substantial evidence that linked five other cancers to being overweight or obese: adenocarcinoma of the esophagus, kidney cancer, colorectal cancer, breast cancer in postmenopausal women, and uterine cancer. This new study reinforces the notion that limiting weight gain over the decades could help to reduce the risk of all 13 cancer types.


    The findings from this study were published today in The New England Journal of Medicine in an article entitled “Body Fatness and Cancer—Viewpoint of the IARC Working Group” and are based on a review of more than 1000 studies of excess weight and cancer risk.


    “The burden of cancer due to being overweight or obese is more extensive than what has been assumed,” explained Graham Colditz, M.D., Dr.P.H., a cancer prevention expert at Washington University School of Medicine in St. Louis, who chaired the IARC Working Group. “Many of the newly identified cancers linked to excess weight haven’t been on people’s radar screens as having a weight component.”


    The IARC team believes that their new findings could have a significant bearing on the global population. Worldwide, an estimated 640 million adults and 110 million children are obese, including one-third of adults and children in the United States.


    “Lifestyle factors such as eating a healthy diet, maintaining a healthy weight, and exercising, in addition to not smoking, can have a significant impact on reducing cancer risk,” Dr. Colditz noted. “Public health efforts to combat cancer should focus on these things that people have some control over.”


    However, Dr. Colditz added that “losing weight is hard for many people. Rather than getting discouraged and giving up, those struggling to take off weight could instead focus on avoiding more weight gain.”


    Interestingly, the investigators found that for most of the cancers on the newly expanded list, a positive dose–response relationship exists, i.e., the higher the body mass index, or BMI, the greater the cancer risk. Moreover, the cancer risks associated with excess weight were similar for men and women and, when data were available, were consistent across geographic regions—North America, Europe, Asia, and the Middle East.


    In addition to providing data linking the excess weight to the additional cancer types, the researchers also looked to provide mechanisms as to why being overweight or obese can increase an individual’s cancer risk. While there are numerous possible explanations, the scientists specifically noted that excess fat leads to an overproduction of estrogen, testosterone, and insulin and also promotes inflammation, all of which can drive cancer growth.


    “Significant numbers of the U.S. and the world’s population are overweight,” Dr. Colditz concluded. “This is another wake-up call. It’s time to take our health and our diets seriously.”

No tags.
NextPrevious

News

  • Medicilon Events
  • Media Coverage
  • Featured Stories

Tags

ADME (11) animal model (3) Animal Models (46) API (3) API process (3) BIAcore 8K (3) bioanalytical testing (3) Clinical Trails (2) consistency evaluation (3) COVID-19 (3) CRO (13) CRO company (8) CRO industry (6) diabetes treatment (3) Drug Discovery (7) drug safety cro (2) Drug Safety Evaluation (3) Elisa Assay (4) Formulation Research (3) GLP (3) green chemistry (3) IND (2) IND Application (3) IND Filing (5) IPO (3) LC-MS (4) Ligand Binding Assay (4) Medicilon Inc. (2) neurological disease (4) neurological diseases (4) neurological disorder (5) neurological disorders (4) PDX model (3) Peptide Drugs (3) Pharmacokinetics (7) pharmacokinetics research (6) pk study (2) Preclinical Research (6) PROTAC (4) Protein expression (4) Protein Purification (8) SAPA (5) Synthetic Biology (4) T cell (3) Western Blot Analysis (2)

Top Posts

  • 14 August, 2017

    Factors Affecting Pharmacokinetics of Drugs

  • 14 October, 2016

    Preclinical Drug Development Process

  • 14 February, 2017

    IND Enabling Studies FDA

Share

About Us

  • Medicilon Overview
  • Executive Team
  • CEO Message
  • Company History
  • Corporate Culture
  • Honor

Services

  • Chemistry
  • Biology
  • Bioanalytical
  • Drug Safety Evaluation
  • Formulation Development
  • Pharmacology
  • Pharmacokinetic
  • Integrated Projects

Customer Center

  • Customer Reviews
  • Download Center
  • Intellectual Property Protection
  • New Models of Collaboration

Contact Us

Shanghai Medicilon Inc.

Address: No. 585, Chuanda Road, Pudong, Shanghai, 201200, China
Email: Marketing@medicilon.com
Website: www.medicilon.com

Copyright 2017 Shanghai Medicilon inc. | All Rights Reserved Privacy Policy
  • Languages
  • 中国日本대한민국
  • Home
  • About
    • Medicilon Overview
    • Executive Team
    • CEO Message
    • Corporate Culture
    • Company History
    • Honor
  • Services
    • Integrated Projects
      • Antibody-Drug-Antibody (ADC)
      • Preclinical Research Services
      • IND Filing
      • Bio Drug Development
      • Chemical Drug Development
      • Chemical Compound Druggability Assessment
      • Molecular Imaging & Radiochemistry
      • OINDP Development
      • Preclinical Ophthalmic Research Platform
    • Pharmacology Services
      • Cancer Xenograft Models
      • Orthotopic Models
      • Syngeneic Mouse Models
      • Transgenic Mouse Model
      • Humanized Mouse Model (hPBMCEngrafted)
      • PDX Model
      • Digestive System Models
      • Neurological Disorders Models
      • Metabolic Disease Models
      • Inflammation & Immunological Disease Models
      • Other Disease Models
    • Chemistry Services
      • Medicinal Chemistry Services
      • Synthetic Chemistry
      • Process Development Services
      • Analytical Chemistry
    • Drug Formulation
      • Pre Formulation Development
      • Analytical Development
      • Formulation Development Services
      • Generics Consistency Evaluation
      • Research on Quality Control
      • Clinical Trial Material
      • OINDP Development
    • Biology Services
      • Discovery Biology Services
      • Recombinant Protein Services
      • Computational Biology & Molecular Modeling
      • Crystallization & Structural Determination
      • Kinase Services
      • SeMet Media Sales
    • Bioanalytical Services
      • Large Molecule Bioanalysis
      • Small Molecule Bioanalysis
    • Pharmacokinetic Services
      • In Vivo Assays
      • In Vitro Assays
    • Drug Safety Evaluation
      • Inhalation Toxicity Assessment
  • Customer
    • Customer Reviews
    • New Models of Collaboration
    • Intellectual Property Protection
    • Download Center
  • Careers
  • News
    • Medicilon Events
    • Media Coverage
    • Featured Stories
  • Contact
Medicilon Inc